Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

OBJECTIVES: To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis, who had insufficient response or intolerance to ≥1 tumour necrosis factor inhibitors (TNFis) or other biological disease-modifying antirheumatic drugs (bDMARDs)....

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S, Kremer, Joel M, Gaich, Carol L, DeLozier, Amy M, Schlichting, Douglas E, Xie, Li, Stoykov, Ivaylo, Rooney, Terence, Bird, Paul, Sánchez Bursón, Juan Miguel, Genovese, Mark C, Combe, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530360/
https://www.ncbi.nlm.nih.gov/pubmed/27799159
http://dx.doi.org/10.1136/annrheumdis-2016-209821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530360/
https://www.ncbi.nlm.nih.gov/pubmed/27799159
http://dx.doi.org/10.1136/annrheumdis-2016-209821

Ejemplares similares